BioXcel Therapeutics, Inc.(BTAI)

$1.41—

Chart

BioXcel Therapeutics, Inc.(BTAI)

NASDAQ

$1.41—

Chart Studio

BTAI(BTAI)

BTAI

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.42

Aug 11, 2026 · Reports before open

Revenue Estimate

$403,315

FY2030E EPS$1.48

Analyst Sentiment

Wall St. Consensus

Hold

15 analysts·Moderate coverage

Score

8 Buy (53%)6 Hold (40%)1 Sell (7%)

Rating Breakdown

Strong Buy

00%

Buy

853%

Hold

640%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

-29.1%

Consensus

$10.00

+609.2%

Bull

$25.00

+1673.0%

12-Month Target Range15 analysts

$1.00$10.00$25.00

Current $1.41Consensus

Current Price

$1.41

Upside to Consensus

$8.59

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1043.34%

EPS—

FY2028

Rev+234.33%

EPS—

FY2029

Rev+182.46%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$19M	$63M	$179M	$399M
Low	$808,257	$9M	$31M	$87M	$195M
High	$2M	$27M	$91M	$258M	$576M
EBITDA Avg	$-993,587	$-11M	$-38M	$-107M	$-240M
Low	$-1M	$-16M	$-55M	$-155M	$-346M
High	$-484,954	$-6M	$-19M	$-52M	$-117M
EBIT Avg	$-993,587	$-11M	$-38M	$-107M	$-240M
Low	$-1M	$-16M	$-55M	$-155M	$-346M
High	$-484,954	$-6M	$-19M	$-52M	$-117M
Net Income Avg	$-20M	$-19M	$-9M	$-8M	$18M
Low	$-26M	$-24M	$-15M	$-12M	$6M
High	$-15M	$-13M	$-3M	$-3M	$28M
EPS Avg	$-1.67	$-1.53	$-0.79	$-0.62	$1.48
Low	$-2.11	$-1.98	$-1.24	$-0.98	$0.50
High	$-1.22	$-1.08	$-0.26	$-0.21	$2.33
Analysts (Rev / EPS)	1 / 1	2 / 2	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$403,315	$396,848	$507,065	$800,000	$1M	$2M	$2M
Low	$403,315	$396,848	$507,065	$800,000	$1M	$2M	$2M
High	$403,315	$396,848	$507,065	$800,000	$1M	$2M	$2M
EBITDA Avg	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
Low	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
High	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
EBIT Avg	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
Low	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
High	$-241,989	$-238,108	$-304,239	$-480,000	$-780,000	$-900,000	$-1M
Net Income Avg	$-5M	$-6M	$-5M	$-4M	$-4M	$-3M	$-3M
Low	$-6M	$-6M	$-5M	$-4M	$-4M	$-3M	$-3M
High	$-4M	$-6M	$-5M	$-4M	$-4M	$-3M	$-3M
EPS Avg	$-0.42	$-0.47	$-0.41	$-0.31	$-0.29	$-0.26	$-0.26
Low	$-0.48	$-0.47	$-0.41	$-0.31	$-0.29	$-0.26	$-0.26
High	$-0.36	$-0.47	$-0.41	$-0.31	$-0.29	$-0.26	$-0.26
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Sep 23, 2024Mizuho Securities

Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI)

Target:$1.00

+69.8%from $0.59

Apr 15, 2024H.C. Wainwright

BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright

Target:$10.00

+244.8%from $2.90

Aug 15, 2023Mizuho Securities

Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy

Target:$4.00

+0.6%from $3.98

Jan 3, 2023H.C. Wainwright

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73

Target:$73.00

+239.9%from $21.48

Nov 11, 2022Guggenheim

Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25

Target:$25.00

+68.7%from $14.82

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance